Analysts think AURA stock price could increase by 334%
Apr 14, 2025, 11:25 AM
-0.09%
What does AURA do
Aura Biosciences, a clinical-stage oncology company based in Boston, develops virus-like drug conjugates (VDCs) to selectively target cancer cells and activate immune responses. Its lead candidate, bel-sar, is in late-stage clinical development for choroidal melanoma and bladder cancer.
8 analysts think AURA stock price will increase by 333.84%. The current median analyst target is $22.95 compared to a current stock price of $5.29. The lowest analysts target is $19.19 and the highest analyst target is $26.25.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
